- Home
- CXM vs EWTX Comparison
CXM vs EWTX Comparison
Compare CXM & EWTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CXM
- EWTX
- Stock Information
- Founded
- CXM 2009
- EWTX 2017
- Country
- CXM United States
- EWTX United States
- Employees
- CXM N/A
- EWTX N/A
- Industry
- CXM Computer Software: Prepackaged Software
- EWTX Biotechnology: Pharmaceutical Preparations
- Sector
- CXM Technology
- EWTX Health Care
- Exchange
- CXM Nasdaq
- EWTX Nasdaq
- Market Cap
- CXM 2.3B
- EWTX 2.7B
- IPO Year
- CXM 2021
- EWTX 2021
- Fundamental
- Price
- CXM $9.37
- EWTX $30.75
- Analyst Decision
- CXM Hold
- EWTX Buy
- Analyst Count
- CXM 15
- EWTX 6
- Target Price
- CXM $9.89
- EWTX $44.83
- AVG Volume (30 Days)
- CXM 3.0M
- EWTX 762.1K
- Earning Date
- CXM 12-04-2024
- EWTX 11-07-2024
- Dividend Yield
- CXM N/A
- EWTX N/A
- EPS Growth
- CXM 36.57
- EWTX N/A
- EPS
- CXM 0.15
- EWTX N/A
- Revenue
- CXM $788,062,000.00
- EWTX N/A
- Revenue This Year
- CXM $8.44
- EWTX N/A
- Revenue Next Year
- CXM $4.31
- EWTX N/A
- P/E Ratio
- CXM $61.43
- EWTX N/A
- Revenue Growth
- CXM 12.02
- EWTX N/A
- 52 Week Low
- CXM $6.91
- EWTX $8.00
- 52 Week High
- CXM $14.32
- EWTX $38.12
- Technical
- Relative Strength Index (RSI)
- CXM 68.88
- EWTX 46.80
- Support Level
- CXM $8.81
- EWTX $27.00
- Resistance Level
- CXM $9.47
- EWTX $35.50
- Average True Range (ATR)
- CXM 0.36
- EWTX 2.36
- MACD
- CXM 0.05
- EWTX -0.10
- Stochastic Oscillator
- CXM 95.24
- EWTX 38.94
About CXM Sprinklr Inc.
Sprinklr Inc is engaged in providing enterprise software that enables every customer-facing function across the front office, from Customer Care to Marketing, to collaborate across internal silos, and communicate across digital channels. Its products include Sprinklr Service, Sprinklr Social, Sprinklr Insights and Sprinklr Marketing. The company operates in Americas, EMEA and other countries. It derives maximum revenue from Americas.
About EWTX Edgewise Therapeutics Inc.
Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of innovative treatments for severe, rare muscle disorders. It is developing orally bioavailable, small molecule therapies for musculoskeletal diseases.